WilmerHale Counsels Agios Pharmaceuticals in Exclusive License Agreement with Aurigene Discovery Technologies

WilmerHale Counsels Agios Pharmaceuticals in Exclusive License Agreement with Aurigene Discovery Technologies

Firm News

Agios Pharmaceuticals, Inc. and Aurigene Discovery Technologies Limited announced a global license agreement to research, develop and commercialize small molecule inhibitors of an undisclosed cancer metabolism target. Under the terms of the agreement, Agios will conduct pre-clinical studies and, if successful, fund further global research and development, as well as regulatory and commercial activities.

The WilmerHale team counseling Agios Pharmaceuticals included Steven Barrett and Mat Trachok.

Read Agios Pharmaceuticals' press release for more information.

Notice

Unless you are an existing client, before communicating with WilmerHale by e-mail (or otherwise), please read the Disclaimer referenced by this link.(The Disclaimer is also accessible from the opening of this website). As noted therein, until you have received from us a written statement that we represent you in a particular manner (an "engagement letter") you should not send to us any confidential information about any such matter. After we have undertaken representation of you concerning a matter, you will be our client, and we may thereafter exchange confidential information freely.

Thank you for your interest in WilmerHale.